TABLE 1.
Patient Characteristics
| Characteristic | All Patients | Sunitinib (n = 46) | Cabozantinib (n = 44) | Crizotinib (n = 28) | Savolitinib (n = 29) |
|---|---|---|---|---|---|
| Median age, years (range) | 68 (58-75) | 65 (58-73) | 65 (58-75) | 68 (61-75) | 67 (58-72) |
| Males, No. (%) | 112 (76) | 35 (76) | 36 (82) | 22 (79) | 19 (86) |
| Race, No. (%) | |||||
| White | 114 (78) | 39 (85) | 32 (73) | 22 (79) | 21 (72) |
| Black | 21 (14) | 5 (11) | 9 (20) | 4 (14) | 3 (10) |
| Other | 12 (4) | 2 (4) | 3 (7) | 2 (8) | 5 (16) |
| Previous systemic therapy, No. (%) | 10 (7) | 3 (7) | 2 (5) | 2 (7) | 3 (10) |
| Histologic subtype (central assessment), No. (%) | |||||
| Type I | 41 (28) | 12 (26) | 14 (32) | 9 (32) | 6 (21) |
| Type II | 63 (43) | 21 (46) | 16 (36) | 13 (46) | 13 (45) |
| IMDC risk group, No. (%) | |||||
| Favorable | 38 (26) | 14 (30) | 10 (23) | 8 (29) | 6 (30) |
| Intermediate | 89 (61) | 26 (57) | 28 (64) | 16 (57) | 19 (66) |
| Poor | 20 (14) | 6 (13) | 6 (14) | 4 (14) | 4 (14) |
| Zubrod PS | |||||
| 0 | 91 (62) | 29 (63) | 29 (66) | 18 (64) | 15 (52) |
| 1 | 56 (38) | 17 (37) | 15 (34) | 10 (36) | 14 (48) |
| Metastatic sites of interest, No. (%) | |||||
| Bones | 26 (18) | 7 (15) | 6 (14) | 5 (18) | 8 (28) |
| CNS | 1 (<1) | 0 (0) | 0 (0) | 1 (<1) | 0 (0) |
| Liver | 38 (26) | 13 (9) | 13 (9) | 4 (3) | 8 (5) |
| Lung | 25 (17) | 7 (5) | 11 (7) | 3 (2) | 4 (3) |
Abbreviations: IMDC, International mRCC Database Consortium; PS, performance status.